Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Stock Short Interest Rises 92.5%

Neuphoria Therapeutics Inc. (NASDAQ:NEUP – Get Free Report) saw a large growth in short interest during the month of October. As of October 30th, there was short interest totaling 12,377 shares, a growth of 92.5% from the October 15th total of 6,429 shares. Based on an average trading volume of 37,998 shares, the short-interest ratio is presently 0.3 days. Approximately 0.2% of the shares of the stock are sold short.

Hedge Funds Weigh In On Neuphoria Therapeutics

A hedge fund recently bought a new position in Neuphoria Therapeutics stock. ADAR1 Capital Management LLC bought a new position in Neuphoria Therapeutics Inc. (NASDAQ:NEUP – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 30,000 shares of the company’s stock, valued at approximately $131,000. ADAR1 Capital Management LLC owned 0.56% of Neuphoria Therapeutics as of its most recent SEC filing. 15.90% of the stock is owned by institutional investors.

Neuphoria Therapeutics Price Performance

Shares of NEUP opened at $2.48 on Tuesday. Neuphoria Therapeutics has a one year low of $2.45 and a one year high of $5.53. The company has a 50-day moving average of $3.34 and a two-hundred day moving average of $4.08. The stock has a market cap of $13.42 million, a price-to-earnings ratio of -0.40 and a beta of 0.77.

Analyst Ratings Changes

NEUP has been the topic of a number of recent research reports. Wall Street Zen upgraded Neuphoria Therapeutics to a “hold” rating in a report on Saturday, July 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neuphoria Therapeutics in a report on Thursday, August 27th. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average price target of $7.00.

Get Our Latest Research Report on NEUP

About Neuphoria Therapeutics

(Get Free Report)

Neuphoria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing investigational treatments for neurological and psychiatric conditions. The company’s work centers on advancing drug candidates intended to address needs in brain health. Its products remain in development rather than being established, marketed therapies. Publicly available information about Neuphoria’s specific development programs, operating geographies and leadership is limited, so no additional details are included here.

See Also

Receive News & Ratings for Neuphoria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuphoria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.